12 / 49
COMBI-d: Post-progression Systemic Therapy
Presented by: Keith T. Flaherty, MD
Post-progression Systemic Therapy
Dabrafenib + Trametinib
(n = 209)
Dabrafenib + Placebo
(n = 211)
Any post-study anticancer therapy, n (%)
101 (48)
130 (62)
Subsequent anticancer therapy, n (%)
Immunotherapy
57 (27)
73 (35)
Ipilimumab
41 (19)
65 (31)
Nivolumab
7 (3)
6 (3)
Pembrolizumab
13 (6)
14 (7)
Radiotherapy
51 (24)
58 (27)
Chemotherapy
37 (18)
50 (24)
Small-molecule targeted therapy
21 (10)
33 (16)
Biological
8 (4)
10 (5)
NP4: 1606042435